scholarly journals Adult acute lymphocytic leukemia: biology and treatment

2011 ◽  
Vol 46 (9) ◽  
pp. 1282-1282
Author(s):  
M Mohty
Keyword(s):  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Adult Acute Lymphocytic Leukemia

Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

2000 ◽  
Vol 18 (3) ◽  
pp. 547-547 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Susan O’Brien ◽  
Terry L. Smith ◽  
Jorge Cortes ◽  
Francis J. Giles ◽  
...  
Keyword(s):  
B Cell ◽  
Acute Lymphocytic Leukemia ◽  
Philadelphia Chromosome ◽  
Lymphocytic Leukemia ◽  
Prognostic Models ◽  
Poor Performance Status ◽  
High Dose ◽  
Cell Disease ◽  
Adult Acute Lymphocytic Leukemia ◽  
Intensive Regimen

PURPOSE: To evaluate the efficacy and toxicity of Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone), a dose-intensive regimen, in adult acute lymphocytic leukemia (ALL). PATIENTS AND METHODS: Adults with newly diagnosed ALL referred since 1992 were entered onto the study; treatment was initiated in 204 patients between 1992 and January 1998. No exclusions were made because of older age, poor performance status, organ dysfunction, or active infection. Median age was 39.5 years; 37% were at least 50 years old. Mature B-cell disease (Burkitt type) was present in 9%, T-cell disease in 17%. Leukocytosis of more than 30 × 109/L was found in 26%, Philadelphia chromosome–positive disease in 16% (20% of patients with assessable metaphases), CNS leukemia at the time of diagnosis in 7%, and a mediastinal mass in 7%. Treatment consisted of four cycles of Hyper-CVAD alternating with four cycles of high-dose methotrexate (MTX) and cytarabine therapy, together with intrathecal CNS prophylaxis and supportive care with antibiotic prophylaxis and granulocyte colony-stimulating factor therapy. Maintenance in patients with nonmature B-cell ALL included 2 years of treatment with mercaptopurine, MTX, vincristine, and prednisone (POMP). RESULTS: Overall, 185 patients (91%) achieved complete remission (CR) and 12 (6%) died during induction therapy. Estimated 5-year survival and 5-year CR rates were 39% and 38%, respectively. The incidence of CNS relapse was low (4%). Compared with 222 patients treated with vincristine, doxorubicin, and dexamethasone (VAD) regimens, our patients had a better CR rate (91% v 75%, P < .01) and CR rate after one course (74% v 55%, P < .01) and better survival (P < .01), and a smaller percentage had more than 5% day 14 blasts (34% v 48%, P = .01). Previous prognostic models remained predictive for outcome with Hyper-CVAD therapy. CONCLUSION: Hyper-CVAD therapy is superior to our previous regimens and should be compared with established regimens in adult ALL.

The importance of cytogenetic studies in adult acute lymphocytic leukemia

1990 ◽  
Vol 89 (5) ◽  
pp. 579-587 ◽  
Author(s):  
Ronald Walters ◽  
Hagop M. Kantarjian ◽  
Michael J. Keating ◽  
Elihu H. Estey ◽  
Jose Trujillo ◽  
...  
Keyword(s):  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Cytogenetic Studies ◽  
Adult Acute Lymphocytic Leukemia

scholarly journals Correction to: Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Ju Bai ◽  
Aili He ◽  
Chen Huang ◽  
Juan Yang ◽  
Wanggang Zhang ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Acute Lymphocytic Leukemia ◽  
Residual Disease ◽  
Lymphocytic Leukemia ◽  
Adult Acute Lymphocytic Leukemia ◽  
Minimal Residual

An amendment to this paper has been published and can be accessed via the original article.

Results of Therapy in Adult Acute Lymphocytic Leukemia

Oncology ◽  
1975 ◽  
Vol 32 (5-6) ◽  
pp. 214-220 ◽  
Author(s):  
Lawrence H. Einhorn ◽  
Steven Meyer ◽  
William H. Bond ◽  
Robert J. Rohn
Keyword(s):  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Adult Acute Lymphocytic Leukemia
Sign in / Sign up

Export Citation Format

Share Document